Sana Biotechnology (NASDAQ:SANA) Stock Price Up 8.9% – Here’s What Happened

Posted by George Bondi on Aug 21st, 2026

Sana Biotechnology, Inc. (NASDAQ:SANA – Get Free Report) was up 8.9% during mid-day trading on Wednesday . The company traded as high as $3.91 and last traded at $3.9540. 589,720 shares changed hands during trading, a decline of 81% from the average daily volume of 3,099,797 shares. The stock had previously closed at $3.63.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on SANA. Weiss Ratings raised shares of Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd. Wall Street Zen downgraded shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Bank of America reduced their price objective on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a report on Friday, August 14th. Finally, Rodman & Renshaw started coverage on Sana Biotechnology in a research report on Monday, May 11th. They issued a “buy” rating and a $16.00 target price on the stock. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Sana Biotechnology presently has a consensus rating of “Moderate Buy” and an average target price of $9.33.

View Our Latest Research Report on SANA

Sana Biotechnology Stock Down 8.8%

The company has a market cap of $1.12 billion, a price-to-earnings ratio of -4.92 and a beta of 2.16. The stock has a fifty day moving average price of $3.45 and a two-hundred day moving average price of $3.42.

Sana Biotechnology (NASDAQ:SANA – Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. Analysts predict that Sana Biotechnology, Inc. will post -0.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in SANA. BlackRock Inc. bought a new position in shares of Sana Biotechnology during the second quarter worth approximately $58,196,000. Canada Pension Plan Investment Board bought a new stake in shares of Sana Biotechnology in the second quarter valued at approximately $35,662,000. Vanguard Group Inc. boosted its stake in shares of Sana Biotechnology by 19.9% in the third quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock valued at $32,408,000 after buying an additional 1,517,474 shares during the period. State Street Corp grew its position in Sana Biotechnology by 20.6% during the fourth quarter. State Street Corp now owns 8,054,841 shares of the company’s stock worth $32,783,000 after buying an additional 1,374,300 shares in the last quarter. Finally, Bank of America Corp DE acquired a new stake in Sana Biotechnology during the second quarter worth approximately $20,062,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

(Get Free Report)

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.